FY2026 EPS Estimates for Kardigan Increased by HC Wainwright

Kardigan, Inc. (NASDAQ:KARD – Free Report) – Analysts at HC Wainwright increased their FY2026 earnings estimates for Kardigan in a research note issued on Thursday, November 12th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($3.70) for the year, up from their prior forecast of ($4.01). HC Wainwright has a “Buy” rating and a $42.00 price objective on the stock. The consensus estimate for Kardigan’s current full-year earnings is ($3.47) per share. HC Wainwright also issued estimates for Kardigan’s Q4 2026 earnings at ($0.83) EPS, Q1 2027 earnings at ($0.92) EPS, Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.84) EPS, FY2027 earnings at ($3.47) EPS, FY2028 earnings at ($3.70) EPS, FY2029 earnings at ($3.92) EPS and FY2030 earnings at ($0.61) EPS.

Other equities analysts have also recently issued research reports about the company. UBS Group assumed coverage on Kardigan in a report on Monday, October 12th. They set a “buy” rating and a $25.00 price target for the company. Weiss Ratings lowered Kardigan from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, November 10th. JPMorgan Chase & Co. dropped their price objective on Kardigan from $51.00 to $46.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 25th. Wall Street Zen cut Kardigan from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Leerink Partners reduced their target price on Kardigan from $37.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.00.

Check Out Our Latest Report on KARD

Kardigan Price Performance

Shares of NASDAQ:KARD opened at $12.85 on Monday. Kardigan has a 52-week low of $12.23 and a 52-week high of $27.00. The firm has a 50-day moving average price of $14.98.

Kardigan (NASDAQ:KARD – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.16.

Hedge Funds Weigh In On Kardigan

Several large investors have recently modified their holdings of KARD. Russell Investments Group Ltd. acquired a new stake in shares of Kardigan during the 3rd quarter worth about $31,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Kardigan during the 3rd quarter worth about $47,000. Legal & General Group Plc bought a new stake in shares of Kardigan during the 2nd quarter worth about $119,000. Squarepoint Ops LLC acquired a new position in Kardigan in the 2nd quarter valued at about $247,000. Finally, Jump Financial LLC acquired a new position in Kardigan in the 3rd quarter valued at about $304,000.

Recent Kardigan Headlines

Investors following KARD have been watching these headlines:

  • Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $3.70 from $4.01, and also improved estimates for FY2028, FY2029 and FY2030. It slightly raised its Q4 2026 estimate as well. The firm maintained its Buy rating and $42 target. HC Wainwright estimates for Kardigan
  • Negative Sentiment: The analyst cut estimates for each quarter of 2027 and lowered its FY2027 EPS forecast to a loss of $3.47 from $3.29. The revisions point to larger expected losses in the near term and could pressure shares.

Kardigan Company Profile

(Get Free Report)

Kardigan is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. Its work centers on advancing therapeutic candidates intended to address heart and vascular conditions. The company’s activities include research and development of a pipeline of cardiovascular drug candidates. Kardigan was launched as a biotechnology company in 2024; detailed information about its commercial products and geographic operations is limited.

Featured Articles

Earnings History and Estimates for Kardigan (NASDAQ:KARD)

Receive News & Ratings for Kardigan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kardigan and related companies with MarketBeat.com's FREE daily email newsletter.